Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research
Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage
Related
- Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin
- Trends in advanced HIV disease, treatment interruption, and viraemia in KwaZulu-Natal, South Africa
- ASSESSMENT OF TREATMENT RESPONSE RESPONSE AND THE ROLE OF COMPLETION SURGERY AFTER CONCURRENT CRTAND BRACHYTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER - A REVIEW FROM THE FRENCH CERVICAL CANCER GUIDELINES GROUP
- Second-line treatment selection for advanced hepatocellular carcinoma: a network meta-analysis with reconstructed survival curves and integrated benefit–risk assessment
- Post-traumatic stress disorder in nursing students on the frontline during the first Covid-19 wave: a cross-sectional survey
BibTeX
@article{wespiser2026lorlatinib,
title = {{Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage}},
author = {Mylène Wespiser and Aurélie Swalduz and Maurice Pérol},
journal = {Translational Lung Cancer Research},
year = {2026},
month = sep,
doi = {10.21037/tlcr-24-903},
url = {https://hal.science/hal-05750216v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage
AU - Mylène Wespiser
AU - Aurélie Swalduz
AU - Maurice Pérol
PY - 2026
DA - 2026/09/15
JO - Translational Lung Cancer Research
DO - 10.21037/tlcr-24-903
UR - https://hal.science/hal-05750216v1
SN - 2218-6751
SN - 2226-4477
ER -